0 Items
Select Page

The Native Antigen Company has been acquired by LGC

World leading infectious disease reagents from the experts

Whether you need cutting-edge reagents for your research or bulk products for manufacturing, we can support your needs

Antigens, Antibodies, Immunoassays

 

We specialise in the development and manufacture of antigens, antibodies and immunoassays for viral and bacterial pathogens. We produce both native and recombinant antigens using our a range of cell expression systems, and have decades of experience in bulk and scale production.

Custom and Contract Research Services

 

We can undertake custom projects to manufacture antigens and other proteins, prepare antibodies and develop immunoassays to support your R&D. Our development laboratories are staffed by a team of PhD molecular biologists and development scientists who are able to execute projects as short as a few days, through to long-term programmes of a year or more.

Mammalian-Expressed Proteins

See our Coronavirus Product Pipeline

The Native Antigen Company is developing an extensive range of antigens and antibodies for the human coronaviruses, including SARS-CoV-2 (COVID-19).

MXRA8 Receptor

The Native Antigen Company has been acquired by LGC

The Native Antigen Company has been acquired by LGC and is now a part of its Clinical Diagnostics unit. For more information, please click the button below.

 

Zika Immunoassay Kit

SARS-CoV-2 S1 and S2 Antigens Now Available

The Native Antigen Company is now offering recombinant S1 and S2 glycoproteins for SARS-CoV-2 (COVID-19) in response to urgent demand.

 

About The Native Antigen Company

 The Native Antigen Company specialises in the development and manufacture of native and recombinant viral and bacterial antigens, antibodies and immunoassays, as well as bespoke product development and custom manufacturing. The company has decades of experience in producing high-quality proteins with its proprietary mammalian cell expression system to ensure correct glycosylation and proper folding. The Native Antigen Company’s high-quality reagents are widely adopted by leading pharmaceutical, in vitro diagnostic assay manufacturers, and academic groups in cutting-edge vaccine research and serology, where correct folding and glycosylation are vital.

Q&A: An Insight Into COVID-19 Serology

During the course of the current coronavirus pandemic, we have all been aware of the urgent need for nucleic acid testing to identify people currently infected with SARS-CoV-2. The second form of testing needed are serological immunoassays, which can identify past...

A Q&A with David Flavell of Leukaemia Busters

In this blog, we speak with Dr. David Flavell about his scientific career, the legacy of Leukaemia Busters, and the recent impact that COVID-19 has had on his research.Tell me about your scientific background David. I was born in a seaside town called Southport in...

Avoiding the Immunopathology Pitfalls of a COVID-19 Vaccine

In the second of a three-part series on COVID-19 vaccines, we explore the potential challenges in stimulating safe vaccine responses and outline the role that diagnostics will play in guiding their development.Rogue Responses Antibodies play a crucial role in...

Designing for Differentiation: Why We Need Highly Specific Diagnostics for a COVID-19 Vaccine

Assessment of vaccine-induced immune responses in clinical trials will require highly specific diagnostic assays to ensure safety. This blog was originally published on Clinical Lab Manager.The Vaccine Race Vaccines are the most effective means of preventing...

An Early Look at Vaccines for COVID-19

In the first of a three-part series on the design, immunology and manufacture of COVID-19 vaccines, we take an early look at the major technologies under development and weigh-up the challenges these vaccines will face in reaching late-phase clinical trials.Why We...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

13 + 9 =

Live Customer Feedback

Join our mailing list

* indicates required